**Abstracts**

**2022-RA-629-ESGO**

**ASSOCIATION OF FOLATE RECEPTOR α EXPRESSION AND TUMOR IMMUNE MICROENVIRONMENT IN PATIENTS WITH CERVICAL CANCER**

1Shu Yazaki, 2Yohi Chiba, 3Yuki Kojima, 4Hiroshi Yoshida, 5Shipemasu Takamizawa, 6Rui Kitadai, 7Ayumi Saito, 8Hitomi Suimyoshi Okuma, 9Tadakki Nishikawa, 10Tatsunori Shimo, 11Kazuki Sudo, 12Emi Noguchi, 13Masaya Uno, 14Misuya Ishikawa, 15Tomoyasu Kato, 16Keiji Furuchi, 17Toshihito Uenaka, 18Yasuhiro Fujitaya, 19Kan Yonomori.

1Medical Oncology, National Cancer Center Hospital, Tokyo, Japan; 2Diagnostic Pathology, National Cancer Center Hospital, Tokyo, Japan; 3Gynecology, National Cancer Center Hospital, Tokyo, Japan; 4Epochal Precision Anti-Cancer Therapeutics (EPAT), Eisai Inc, Exton, PA

10.1136/ijgc-2022-ESGO.39

**Introduction/Background**

Folate receptor α (FRα) is an attractive target for cancer treatment based on its expression profile. We previously reported that FRα expression was higher in cervical adenocarcinoma than in squamous cell carcinoma (SCC) and associated with poor survival (Takamizawa et al., AACC 2021). However, the relationship between FRα and the immune microenvironment remains unknown.

**Methodology**

We performed immunohistochemical analysis of whole tumor sections from patients with cervical cancer who underwent primary surgery between 2000 and 2020 at our institution. FRα expression was evaluated using anti-FRα monoclonal antibody clone 26B3. FRα-positive and FRα-high were defined as ≥5% of tumor staining and as H-score ≥60. PD-L1 expression (clone 2C3) was assessed according to the combined positive score (CPS). The density of intratumoral CD3 and CD8 were calculated as the average number of positive cells in the five independent areas. The association between FRα expression and immune biomarkers was analyzed.

**Results**

Overall, 123 patients were evaluated, and 67 were SCC and 56 were non-SCC. FRα-positive and FRα-high were identified in 72.4% and 27.6%. PD-L1 was positive (CPS≥1) in 75.6% and more commonly expressed in SCC (SCC vs. non-SCC: 83.5% vs. 66.1%, p=0.02). FRα expression showed a significantly negative correlation with PD-L1 expression (r=-0.22, p<0.001), and median (IQR) PD-L1 CPS was 20 (5–60) in FRα-negative and 5 (0–25) in FRα-positive group (p=0.04). FRα-positive was more frequent in PD-L1 CPS<10 groups than in PD-L1 CPS≥10 groups (81% vs. 64%, p=0.03). Median CD3 and CD8 counts were not different between FRα-negative and FRα-positive groups.

**Conclusion**

In cervical cancer, FRα expression negatively correlates with PD-L1 expression and is more common in the PD-L1 CPS<10 groups. Our findings suggest that FRα-expression may be a potential therapeutic target for cervical cancer with low/negative PD-L1 expression.

---

**2022-RA-622-ESGO**

**COMPARISON BETWEEN BRICKER VS DOUBLE-BARRELED WET COLOSTOMY AFTER PELVIC EXENTERATION**

1Víctor Lago, 2Blanca Segarra, 3Tamara Pradillo, 4Pablo Padilla Iserne, 5Luis Matute, 6Marta Gurrea, 7Santiago Domingo. 1University Hospital La Fe, Valencia, Spain; 2CEU San Pablo University, Valencia, Spain; 3University Hospital Infanta Elena, Madrid, Spain

10.1136/ijgc-2022-ESGO.38

**Introduction/Background**

Pelvic exenteration is performed in patients who suffer from relapsed gynecologic tumours, with most of them requiring some sort of urinary diversion.

**Methodology**

The main objective of this study was to assess the urinary complications associated with the Bricker ileal conduit versus double-barrelled wet colostomy after performing a pelvic exenteration for gynecologic malignancies.

**Results**

A total of 61 pelvic exenterations were identified between November 2010 and April 2022; 29 Bricker ileal conduits and 20 double-barrelled wet colostomies were included in the urinary diversion analysis. Regarding the specific short-term urinary complications, no differences were found in the rate of urinary leakage (3 vs 0%; p = 1), urostomy complications (7 vs 0%; p = 0.51), acute renal failure (10 vs 20%; p = 0.24) or urinary infection (0 vs 5%; p = 0.41). Up to 69% of patients with Bricker ileal conduits and 65% of double-barrelled wet colostomies (p = 0.76) presented specific medium/long-term urinary complications. No differences in the rates of pyelonephritis (59 vs 53%; p = 0.71), urinary fistula (0 vs 12%; p = 0.13), ureteral stricture (10 vs 6%; p = 1), conduit failure and reconstruction (7 vs 0%; p = 0.53), renal failure (38 vs 29%; p = 0.56) or electrolyte disorders (24 vs 18%; p = 0.72) were found. The OS (Overall survival) after pelvic exenteration at 12 and 48 months was 77% and 58%, respectively. The DFS (Disease Free Survival) at 12 and 48 months after pelvic exenteration was 64% and 51%, respectively.

**Conclusion**

Between double-barrelled wet colostomy and the Bricker ileal conduit, the related urinary complications remained high regardless of the type of technique. In this context, the double-barrelled wet colostomy presents advantages such as the single stoma placement and the simplicity of the technique.

---

**2022-VA-633-ESGO**

**STANDARDIZED LEEF PROCEDURE**

1Víctor Lago, 2Blanca Segarra-Vidal, 3Pablo Padilla-Iserne, 4Luis Matute, 5Marta Gurrea, 6Jose Antonio Pérez Álvarez, 7Santiago Domingo. 1University Hospital La Fe, Valencia, Spain; 2University Hospital Nuestra señora de la candelaria, Tenerife, Spain

10.1136/ijgc-2022-ESGO.40

**Introduction/Background**

Recurrence of cervical cancer is a challenge especially in patients who have received Radiochemotherapy for local extension at diagnosis. It is relatively